GLP-1“三国杀”开局?辉瑞百亿锁定Metsera,诺和诺德中国出招应战

医药经济报
Nov 12, 2025

全球GLP-1市场竞争升级。11月11日,业内传出诺和诺德中国组织架构调整新消息,从2026年1月1日起,新兴事业部(EBD)正式更名为胰岛素事业部,剥离原GLP-1相关业务。肥胖症与糖尿病事业部(DOD)则强化GLP-1核心地位,全面承接司美格鲁肽全场景业务,巩固糖尿病领域优势。在此项调整公布之际,辉瑞以100亿美元锁定临床阶段减肥药“新贵”Metsera的全部股权,值得注意的是,诺和诺德也曾...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10